A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Candesartan cilexetil/nifedipine (Primary) ; Candesartan cilexetil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Bayer; Bayer HealthCare
- 11 Oct 2019 This trial was discontinued in France, according to European Clinical Trials Database.
- 13 Jun 2019 The trial has been discontinued in UK
- 06 Feb 2019 The trial has been discontinued in Czech Republic.